Humanigen Inc (NASDAQ:HGEN) (FRA:0KB2) has completed patient enrollment in its Phase 1 bioimaging study of ifabotuzumab to treat recurrent brain cancer - glioblastoma multiforme (GBM).
The primary goal of this Phase 1 trial is to evaluate the safety of ifabotuzumab and to recommend a dose for a potential Phase 2 study, either with ifabotuzumab or an antibody drug conjugate (ADC) based on ifabotuzumab.
READ: Humanigen creates Australian entity to help drive Asia-Pacific growth
GBM is the most frequent and lethal type of primary brain cancer, with only 10% of patients surviving five years.
Humanigen's trial is located at the Olivia Newton-John Cancer Research Institute in Victoria, Australia and results are expected in the first half of 2021. It is supported by funding from the Cure Brain Cancer Foundation.
"The study has now completed recruitment and we are very excited at having shown that ifabotuzumab is able to target the brain tumor in all the patients tested without binding to healthy tissue," said Professor Hui Gan, the clinical research lead, in a statement.
"We saw some signs that ifabotuzumab was affecting the blood vessels that feed the tumors and may halt their ability to grow in some patients."
Humanigen is developing its portfolio of clinical and pre-clinical therapies for treating cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.
In a separate statement, Humanigen said that its management will present and host meetings with investors and potential partners at the J.P. Morgan Healthcare Conference, held virtually from January 11 to 14, 2021.
Contact the author at giles@proactiveinvestors.com
